Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer

Clinical Imaging

Volumn 32, Issue 1, 2008, Pages 32-37

  Wang, Hui ^a   Fu, Hong Liang ^a   Li, Jia Ning ^a   Zhou, Ren Jian ^a   Hui Gu, Zhen ^a   Wu, Jing Chuan ^a   Huang, Gang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

131I whole body scan; 18F FDG SPECT; Thyroid cancer

Indexed keywords

COMPUTERIZED TOMOGRAPHY; PATIENT TREATMENT; SENSITIVITY ANALYSIS; TUMORS;

F-FDG SPECT; SCINTIGRAPHY; THYROID CANCER; WHOLE-BODY SCAN;

MEDICAL IMAGING;

FLUORODEOXYGLUCOSE F 18; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER; WHOLE BODY SCINTISCANNING; COMPARATIVE STUDY; MIDDLE AGED; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; THYROIDECTOMY; WHOLE BODY COUNTING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY COUNTING;

EID: 37349078700     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2007.07.010     Document Type: Article

References (21)

1. Romer W., Hanauske A., Ziegler S., Thodtmann R., Weber W., Fuchs C., Enne W., Herz M., Nerl C., Garbrecht M., and Schwaiger M. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91 (1998) 4464-4471
2. Hoekstra C., Paglianiti I., Hoekstra O., Smit E., Postmus P., Teule G., and Lammertsma A. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med (2000) 731-743
3. Moore J., Waller M., Zhao S., Dodd N., Acton P., Jeavons A., and Hastings D. Feasibility of imaging photodynamic injure to tumors by high-resolution positron emission, tomography. Eur J Nucl Med 25 (1998) 1248-1254
4. Pacak K., Eisenhofer G., and Goldstein D. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 25 (2004) 568-580
5. Khan N., Oriuchi N., Higuchi T., Zhang H., and Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 76 (2003) 690-695
6. Wang W., Macapinlac H., Larson S., Yeh S., Akhurst T., Finn R., Rosai J., and Robbins R. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84 (1999) 2291-2302
7. Feine U., Lietzenmayer R., Hanke J., Held J., Wohrle H., and Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
8. Helal B., Meriet P., Toubert M., Franc B., Schvartz C., Gauthier-Koelesnikov H., Prigent A., and Syrota A. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42 (2001) 1464-1469
9. Grunwald F., Schomburg A., Bender H., Klemm E., Menzel C., Bultmann T., Palmedo H., Ruhlmann J., Kozak B., and Biersack H. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23 (1996) 312-319
10. Dietlein M., Scheidhauer K., Voth E., Theissen P., and Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24 (1997) 1342-1348
11. Grunwald F., Kalicke T., Feine U., Lietzenmayer R., Scheidhauer K., Dietlein M., Schober O., Lerch H., Brandt-Mainz K., Burchert W., Hiltermann G., Cremerius U., and Biersack H. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 26 (1999) 1547-1552
12. Altenvoerde G., Lerch H., Kuwert T., Matheja P., Schafers M., and Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 383 (1998) 160-163
13. Grunwald F., Menzel C., Bender H., Palmedo H., Willkomm P., Ruhlmann J., Franckson T., and Biersack H. Comparison of 18FDG-PET with 131iodine and 99 mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7 (1997) 327-335
14. Maxon H. Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid 9 (1999) 443-446
15. Stokkel M., de Klerk J., Zelissen P., Koppeschaar H., and van Rijk P. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 26 (1999) 1606-1609
16. Giammarile F., Hafdi Z., Bournaud C., Janier M., Houzard C., Desuzinges C., Itti R., Sassolas G., and Borson-Chazot F. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?. Eur J Endocrinol 149 (2003) 293-300
17. Frilling A., Gorges R., Tecklenborg K., Gassmann P., Bockhom M., Clausen M., and Broelsch C. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 128 (2000) 1067-1074
18. Mansi L., Moncayo R., Cuccurullo V., Dottorini M., and Rambaldi P. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl Med Imaging 48 (2004) 82-95
19. Ong S., Ng D., and Sundram F. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Singapore Med J 46 (2005) 297-301
20. Min J.-J., Chung J.-K., and Lee Y. Relationship between differentiation and expression of sodium/iodide symporter or glucose transporter-1 in differentiated thyroid carcinoma. J Nucl Med 42 Suppl (2001) 133
21. Lazar V., Bidart J., Caillou B., Mahe C., Lacroix L., Filetti S., and Schlumberger M. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84 (1999) 3228-3234